Article

RA Mortality Rates Same in Patients Receiving Various Biologics

There was no significant difference in the rates of death among study patients with rheumatoid arthritis who were exposed to one of several tumor necrosis factor inhibitors used to manage RA.

There was no significant difference in the rates of death among study patients with rheumatoid arthritis (RA) who were exposed to one of several tumor necrosis factor (TNF) inhibitors used to manage RA. Researchers linked data from the Swedish Biologics Register, a comprehensive database of patients for whom first-ever biologic therapy for rheumatologic diseases was being started, and information from national Swedish registers (including all-cause mortality, demographics, RA characteristics, and other data). There were more than 19,000 person-years of follow-up in the 5-year study period, during which time 3.3% of the patients died.

Although no statistically significant difference in mortality rates across 3 biologic therapies (adalimumab, etanercept, and infliximab) was found, further studies are needed to determine whether that would hold across various subsets of patients with RA, it was noted. This population-based study of patients with RA, the first to compare mortality rates among patients treated with individual TNF inhibitors, was published in Arthritis & Rheumatism, an American College of Rheumatology publication.

Related Videos
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2025 MJH Life Sciences

All rights reserved.